Last reviewed · How we verify
Cinobufacini Injection
Cinobufacini is a bufadienolide compound derived from toad venom that inhibits cell proliferation and induces apoptosis in cancer cells through multiple pathways.
Cinobufacini is a bufadienolide compound derived from toad venom that inhibits cell proliferation and induces apoptosis in cancer cells through multiple pathways. Used for Hepatocellular carcinoma, Gastric cancer, Lung cancer.
At a glance
| Generic name | Cinobufacini Injection |
|---|---|
| Sponsor | Dongfang Hospital Beijing University of Chinese Medicine |
| Drug class | Natural product bufadienolide; cardiac glycoside analog |
| Target | Na+/K+-ATPase; multiple apoptotic pathways |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Cinobufacini acts as a cardiac glycoside-like agent that interferes with Na+/K+-ATPase and triggers apoptotic pathways in malignant cells. It has been shown to inhibit tumor cell growth, induce differentiation, and modulate immune responses. The drug is used in traditional Chinese medicine-based oncology and is believed to work through both direct cytotoxic effects and immunomodulatory mechanisms.
Approved indications
- Hepatocellular carcinoma
- Gastric cancer
- Lung cancer
- Other solid tumors (as adjunctive therapy in traditional Chinese medicine practice)
Common side effects
- Nausea and vomiting
- Gastrointestinal discomfort
- Cardiac arrhythmias
- Electrolyte imbalance
Key clinical trials
- Clinical Trial of Cinobufacini Combined With Transarterial Chemoembolization (TACE) on Primary Liver Cancer (PHASE4)
- A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites (PHASE1)
- Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma (PHASE4)
- Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: